Attached files
| file | filename |
|---|---|
| EX-99.2 - EXHIBIT 99.2 - FENNEC PHARMACEUTICALS INC. | v475143_ex99-2.htm |
| EX-99.1 - EXHIBIT 99.1 - FENNEC PHARMACEUTICALS INC. | v475143_ex99-1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
Current Report
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 13, 2017
FENNEC PHARMACEUTICALS INC.
(Exact name of registrant as specified in its charter)
| 001-32295 (Commission File Number) | ||
| British Columbia, Canada | 20-0442384 | |
| (State or other jurisdiction of incorporation) |
(I.R.S. Employer Identification No.) | |
| PO Box 13628, 68 TW Alexander Drive, Research Triangle Park, NC |
27709 | |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code: (919) 636-4530
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
| Item 8.01 | Other Events. |
On September 11, 2017, Fennec Pharmaceuticals Inc. (“Fennec”) issued a press release announcing that its shares of common stock were approved for listing on the Nasdaq Capital Market ("Nasdaq"). Fennec commenced trading on Nasdaq under the symbol “FENC” on September 13, 2017. A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K.
On September 13, 2017, Fennec announced the preliminary results of the SIOPEL 6 study on PEDMARKTM (sodium thiosulfate) to be presented at the 49th congress of the international society of pediatric oncology (SIOP) 2017 meeting. The SIOP conference committee has advised of the acceptance of a SIOPEL 6 abstract for presentation during the late breaker session on Saturday, October 14, 2017 at SIOP 2017 in Washington, DC. A copy of the press release is filed as Exhibit 99.2 to this Current Report on Form 8-K.
| Item 9.01 | Financial Statements and Exhibits. |
| (d) | Exhibits. |
| Exhibit No. | Description |
| Exhibit 99.1 | Press Release dated September 11, 2017 | |
| Exhibit 99.2 | Press Release dated September 13, 2017 |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| FENNEC PHARMACEUTICALS INC. | |||
| Date September 13, 2017 | By: | /s/ Rostislav Raykov | |
| Rostislav Raykov | |||
| Chief Executive Officer | |||